Margaret Foster Riley
Margaret (Mimi) Foster Riley is a professor at the University of Virginia School of Law, with a secondary appointment at the School of Medicine and a program affiliation with the Batten School of Leadership and Public Policy. She teaches food and drug law, health law, animal law, bioethics, regulation of clinical research and public health law. Riley has written and presented extensively about health care law, biomedical research, genetics, reproductive technologies, stem cell research, animal biotechnology, health disparities and chronic disease. She is the Director of UVA’s Program in Animal Law. She serves as chair of UVA’s Embryonic Stem Cell Research Oversight Committee and as legal advisor to the Health Sciences Institutional Review Board. She served on the National Research Council Committee on Revisions to the Common Rule for the Protection of Human Subjects, the Committee on Controlled Human Exposure Studies at EPA and was a consultant on the Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse. She has advised numerous committees of the National Academy of Medicine and the Virginia Bar. Before coming to Virginia, Riley was an associate with Pepper Hamilton & Scheetz in Philadelphia, where she worked primarily in complex securities, commercial and mass tort litigation. Prior to that position, she was a litigation associate with Rogers & Wells in New York. Riley received her law degree from Columbia University and her bachelor of arts from Duke University.
Chris Green is the Executive Director of Harvard Law School’s Animal Law & Policy Program. He is a graduate of Harvard Law School and the University of Illinois, where he created the school’s first Environmental Science degree. Chris a former Chair of the American Bar Association’s TIPS Animal Law Committee, and previously was the Director of Legislative Affairs for the Animal Legal Defense Fund. Chris currently serves on the Executive Board of the National Sheriffs' Association’s Coalition on Violence Against Animals, previously served on the Board of the National Center for Animal Law, was an advisor to the National Canine Research Council, and is a member of both the American Veterinary Medical Law Association and the Illinois Farm Bureau. Chris was a member of the California Veterinary Medical Association’s Non-Economic Recovery Task Force, helping explore legislative options to balance the profession’s increasing liability exposure with a more equitable assessment of companion animal value. He later acted as an advisor to members of the American Veterinary Medical Association’s Task Force on the Legal Status of Animals, addressing those same legislative issues at a national level. This year, Chris served on the National Academies committee that organized the Workshop on Future Directions for Laboratory Animal Law in the United States (2017-2018) and co-hosted the event at Harvard Law School. Chris has consulted on animal legal issues for CNN, CBS News, NBC News, Headline News, POLITICO, The Atlantic, Bloomberg News, Harper’s, Huffington Post, Science Magazine, Smart Money Magazine, The New York Times, Chicago Tribune, San Francisco Chronicle, Wall Street Journal, and Washington Post. He also has spent the past 20 years managing an Illinois farm that has remained in his family for 180 consecutive years.
Joan C. Hendricks
Joan C. Hendricks served on the faculty of the University of Pennsylvania School of Veterinary Medicine for more than 20 years. Her research focused on sleep biology. She conducted NIH-supported biomedical studies in animals from cats to English bulldogs to fruitflies, from 1980 until becoming Dean. In 2001 she was named the Henry and Corinne R. Bower Professor of Small Animal Medicine, the first woman to be named to an endowed professorship at the school. Dr. Hendricks also served as chief of critical care in the Department of Clinical Studies at Philadelphia, she was the founding director of the Veterinary Clinical Investigation Center (VCIC) at the school, and she held a secondary appointment as professor in the Department of Medicine at Penn Medicine. She is a recognized expert in the field of sleep and sleep disorders and has, for decades, studied the physiology and anatomy of sleep and an animal model of sleep apnea (the English bulldog). She later on switched to using Drosophila as a model to study sleep and sleep disorders. From 2006 to 2018, Dr. Hendricks was the Gilbert S. Kahn Dean of Veterinary Medicine at the School of Veterinary Medicine. In this capacity, she oversaw all research conducted in the School and in collaborations across Penn. Penn Vet has the largest portfolio of individual NIH-supported grants of any veterinary school in the United States. Dr. Hendricks has a BS in biology and psychology from Yale University and a VMD and PhD from the University of Pennsylvania. Dr. Hendricks currently is on terminal sabbatical and will retire effective August 1, 2019. As the daughter of a career Army officer, Dr. Hendricks has a personal interest in the health and wellbeing of Veterans.
Kathrin Herrmann is a veterinarian and assistant scientist at the Center for Alternatives to Animal Testing (CAAT) at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. At CAAT-US as well as CAAT-Europe (based at the University of Konstanz, Germany), she coordinates the Refinement Program. During her veterinary training, which involved studies in Berlin, Germany and Zürich, Switzerland, and clinical trainings at Cornell University, USA, Massey University, NZ, and University of Pretoria, SA, Kathrin was engaged in many animal protection issues. Animal experimentation and the 3Rs have been her primary focus since she became a research fellow at the Animals Scientific Procedures Inspectorate in Berlin (2007-2017). After a 4-year residency program, Kathrin became a veterinary specialist of animal welfare and ethics in Germany in 2014. Since 2016, she is an accredited European Specialist in Animal Welfare Science, Ethics and Law with the European College of Animal Welfare and Behavioural Medicine. For her PhD studies (2012-2018), supervised by Professor Paul Flecknell, she reviewed German animal research applications to determine whether all existing refinement measures were being proposed as a means of reducing animal suffering to the absolute minimum. Her other interests relate to advocating for openness and public engagement in animal experimentation and for humane education. Kathrin also raises awareness of the important role veterinarians should play in animal protection. She is the initiator and co-editor of the forthcoming book “Animal Experimentation: Working Towards a Paradigm Change” (Brill, Vol. 22), which features 51 authors who review current animal use in science, present new and innovative non-animal approaches to address urgent scientific questions, and offer a roadmap towards replacement. "Animal Experimentation: Working Towards a Paradigm Change" will be available through open access in early 2019.
Jonathan Kimmelman is the James McGill Professor in the Biomedical Ethics Unit/Social Studies of Medicine of McGill University. He has cross appointments in Experimental Medicine, Epidemiology, Biostatistics and Occupational Health, and Human Genetics. Kimmelman holds a PhD in molecular biophysics and biochemistry from Yale University, and joined McGill in 2005. His research revolves around the ethical, social and policy dimensions of translational research. He received the Institute of Genetics Maud Menten New Investigator Prize, a Canadian Institutes of Health Research (CIHR) New Investigator Award (2008) and a Friedrich Bessel-Humboldt Award (2014). Kimmelman chaired the ethics committee of the American Society of Gene and Cell Therapy, 2008-2010, and International Society of Stem Cell Research (2014-2016). He also served on the CIHR Stem Cell Oversight Committee, serves on several DSMBs of the U.S. NIH, and has been a member of three National Academies committee reports. His book, Gene Transfer and the Ethics of First-in-Human Trials: Lost in Translation, was published by Cambridge University Press. In 2018, he was named as a Hastings Center Fellow. Kimmelman's research centers on the ethical, social, and policy challenges in testing novel medical technologies in human beings ("translational clinical research"). Current projects are investigating risk, prediction, validity, and knowledge value across the trajectory of drug development. Another set of projects is pursuing alternative frameworks and understandings concerning the role and content of clinical research ethics. Kimmelman directs the Studies of Translation, Ethics, and Medicine (STREAM) research group.
Lewis B. Kinter
Lewis Kinter, Ph.D., D.A.B.T., Fellow A.T.S., is currently President and Principal Scientist at GLP Scientific Consulting, Unionville, PA, USA. He has been engaged in pharmaceutical, biological, and medical device research and development for over 35 years and is an internationally recognized expert in cardiovascular/renal physiology, pharmacology, toxicology, and nonclinical R&D. Dr. Kinter received his BS in Biology at Union College (1973) and his doctorate in Medical Physiology from Harvard University (1978). From 1981 to 2014, he held positions of increasing responsibility in biomedical R&D with Smith Kline & French, SmithKline Beecham, Sterling Winthrop, Nycomed Amersham, Astra Merck, and AstraZeneca. Dr. Kinter is a Diplomate of the American Board of Toxicology, Fellow of the Academy of Toxicological Sciences, Professor of Pharmacology & Toxicology (Adjunct) Michigan State University, and former Professor of Physiology (adjunct) University of Pennsylvania School of Medicine. He has authored over 100 research manuscripts and book chapters, and organized/participated in numerous courses, workshops, symposia, and professional meetings in basic and applied physiology, pharmacology, toxicology, and nonclinical pharmaceutical R&D. Dr. Kinter currently holds memberships in the American Physiological Society (38 yrs.), American Society for Pharmacology and Experimental Therapeutics (31 yrs.), Society of Toxicology (21 yrs.), and Safety Pharmacology Society (18 yrs). He is a founder and former president of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium), a former chairman of the Pharmaceutical Research and Manufacturers’ Association (PhRMA) Preclinical Sciences Leadership Group (DRUSAFE), and founder and former president of the Safety Pharmacology Society. Throughout his career, Dr Kinter has served as research scientist, co-investigator, principle investigator, study director, and/or department manager/director for authorized in vivo physiological, pharmacological, and toxicological investigations in vertebrates including fish, mice, rats, rabbits, ferrets, swine, dogs, and non-human primates (NHPs). He is accomplished in small animal survival surgery and championed early use of chronically implanted vascular catheters, sensors, and telemetry devices in mice, rats, rabbits, dogs and NHPs to improve scientific data quality and laboratory efficiency, and to reduce animal use (3Rs Refinement and Reduction objectives). His efforts have been recognized to reduce annual animal use in susceptible applications by 75% or more. Dr. Kinter has been an active participant, member, and chair of Animal Care and Use Committees (IACUCs) in several organizations in which he was employed or volunteered. Dr. Kinter continues to serve in leadership capacities on several Boards of professional scientific and charitable organizations.
Sarah L. Lathrop
Sarah L. Lathrop, DVM, PhD, is a Professor of Pathology at the University of New Mexico (UNM) School of Medicine, currently conducting research on infectious diseases and injury. After receiving her BS in animal science from Colorado State University, she earned her DVM from the University of Minnesota College of Veterinary Medicine. She practiced both small and large animal clinical veterinary medicine in Cortez, Colorado, and then completed a PhD in veterinary preventive medicine at Ohio State University, focusing on infectious disease research in cattle while also providing veterinary care for gnotobiotic research animals at the Ohio Agricultural Research and Development Center. Dr. Lathrop served a two-year post-doctoral fellowship at the Centers for Disease Control and Prevention (CDC) as an Epidemic Intelligence Service Officer, studying vector-borne infectious diseases such as plague, tularemia, and dengue and the impact of zoonotic diseases. She then conducted vaccine research in cattle, swine, dogs and cats at Merial’s Athens Clinical Unit in Georgia, focusing on vaccine development and licensure. Dr. Lathrop joined UNM in 2003 to conduct research on infectious diseases and injury, with continuous extramural funding from the CDC and more recently, the Department of Defense. She also serves as the Principal Investigator for the Foodborne Diseases Active Surveillance Network portion of New Mexico's Emerging Infections Program (EIP), managing a staff of 10 researchers. She has served on numerous Institutional Animal Care and Use Committees (IACUCs), biosafety committees, and scientific review committees for tissue repositories, as well as a reviewer for numerous peer-reviewed journals.
Vince Mendenhall received his Doctor of Veterinary Medicine degree at Colorado State University (CSU) in 1968, and his Ph.D. in Experimental Surgery/Comparative Anatomy, also from CSU, in 1981. In 1975, he joined 3M Company where he developed their Department of Surgical Research as it related to Medical Device development. There, he worked in all areas of experimental surgical techniques, including neuro-orthopedic, ophthalmic, cardiovascular, microvascular, wound healing, and abdominal surgery in all species of laboratory animals, including many studies involving, when appropriate, canines as the Test System. He completed more than 500 research projects in these areas in the 17 years he was at 3M. He continued these efforts at Primedica/Charles River’s Preclinical Services, Massachusetts, from 1993 to 2008, developing many new surgical models for Safety Pharmacology, Pharmacokinetics (PK) and Experimental Medicine which initially did primarily involve dogs. He continued all of these efforts and his long career in experimental surgery as Director of Preclinical Surgical Services at Wake Forest Innovations, from 2008 to 2015. He now consults with sponsors on preclinical study designs for necessary animal studies on newly developed medical devices in all specialties, performing extensive discovery and developmental work along with pilot studies to establish a definitive GLP protocol. During the developmental stages, he emphasizes the importance of selection of the correct animal model and other techniques in order to gain definitive results that are translatable to the human condition. He is also extensively involved in telemetry safety pharmacology studies and specialized toxicology studies, primarily involving dogs, from the standpoint of targeted drug delivery and specialized PK, e.g., intrathecal catheterizations for the study of CSF dynamics, bile duct implants along with portal vein and hepatic artery catheterizations to study first pass metabolism PK, as well as thoracic duct lymphatic PK. He is known worldwide for his innovative surgical techniques in all surgical specialties. To date, he has presented the results of his developmental and definitive work at 182 national and international peer reviewed meetings, published 12 book chapters, and 29 referred publications. He has received many awards for his work in these areas from organizations such as the Academy of Surgical Research (of which he was President in 2005), the Society for Biomaterials, the European Intraocular Implantlens Commission, The European Society of Arthroscopy and Knee Surgery, and local AALAS organizations. He was awarded the Jacob Markowitz award by the Academy of Surgical Research in 2018 for his pioneering work in the field of Preclinical Experimental Surgery.
Christian E. Newcomer
Christian E. Newcomer, V.M.D., M.S., DACLAM is a 1977 graduate of the School of Veterinary Medicine at the University of Pennsylvania. Following a year as a research associate/large animal intern at The Pennsylvania State University (1977-78), he entered post-doctoral training in laboratory animal medicine at the University of Michigan (1978-81) and became board certified as a Diplomate in the American College of Laboratory Animal Medicine (ACLAM) in 1982. During his career he held clinical, academic and leadership positions in laboratory animal medicine at the Massachusetts Institute of Technology (1981-87), Tufts-New England Medical Center and Tufts University School of Veterinary Medicine (1987-1994), University of North Carolina at Chapel Hill (1994-2001), the Veterinary Resources Program at National Institutes of Health (2001-2003) and Johns Hopkins University (2003-2008). In 2008 he joined AAALAC International as Executive Director capping more than 25 years of involvement with that organization as an ad hoc site visitor and member of the Council on Accreditation and retaining the title Executive Director Emeritus upon retirement in 2016. He is a past-president of the American College of Laboratory Animal Medicine (1996) and of the American Association for Laboratory Animal Science (2008) and vice president of the AAALAC International Council on Accreditation (1996-98). He served as a member of the ILAR/NRC Committee on Occupational Health and Safety in Research Animal Facilities (1993-96) and chairman of the Committee on Cost of and Payment for Animal Research Institute for Laboratory Animal Research (1997-2000). He also has authored 26 peer-reviewed articles and 22 book chapters and has spoken extensively on many topics to promote the quality of care for research animal subjects and the discussion of the ethical considerations of their use. Currently, he remains active in laboratory animal medicine/science as an independent consultant and as a member of the Interagency Collaborative Animal Research Education (ICARE) Project faculty.
William Z. Potter
William Z. Potter earned his B.A., M.S., M.D., and Ph.D. at Indiana University, after which he functioned in positions of increasing responsibility and seniority over the next 25 years at the National Institutes of Health (NIH) with a research focus on translational neuroscience. While at the NIH, Bill was widely published and appointed to many societies, committees and boards; these roles enabled him to develop a wide reputation as an expert in psychopharmacological sciences and championing the development of novel treatments for central nervous system (CNS) disorders. Bill left the NIH in 1996 to accept a position as Executive Director for early clinical neuroscience at Lilly Research Labs, and in 2004 he joined Merck Research Labs (MRL) as Vice President of Clinical Neuroscience, then moved to the newly created position of Translational Neuroscience in 2006, a position from which he retired in January of 2011. His experience at Lilly and MRL in identifying, expanding and developing methods of evaluating CNS effects of compounds in human brain cover state-of-the-art approaches across multiple modalities. These include brain imaging and cerebrospinal fluid proteomics as well as development of more sensitive clinical measures. Bill continues as an Emeritus co-chair of the Neuroscience Steering Committee of the Foundation for the National Institutes of Health (FNIH) and serves as a Senior Advisor to the Director of the National Institutes of Mental Health (NIMH), where he champions the position that more disciplined hypothesis testing of targets in humans through public/private partnerships is the best near-term approach to moving CNS drug development forward for important neurologic and psychiatric illnesses.
David M. Powell
David M. Powell joined the Saint Louis Zoo as Director of Research in August 2016. He is responsible for oversight of behavioral, reproductive, and endocrine research, as well as some visitor studies research. Prior to coming to Saint Louis, David was Associate Curator of Mammals at the Wildlife Conservation Society's Bronx Zoo in New York for 12 years, where he developed a strong background in captive mammal management and husbandry. David received his Ph.D. from the University of Maryland for his studies of behavior and reproductive biology in the feral horses on Assateague Island. David did his post doctoral studies at the Smithsonian Institution's National Zoological Park in the Department of Conservation Biology studying giant panda behavior in U.S. and Chinese zoos for four years. David also worked at Zoo Atlanta from 1988-1993 in various roles, including animal keeper, animal diet technician, and research intern. He is actively involved in the Association of Zoos and Aquariums (AZA) professional activities including serving on Taxon Advisory Group steering committees, managing breeding programs and serving on the AZA Animal Welfare and Wildlife Conservation & Management Committee. He currently serves on the Research Review Committee of the Saint Louis Zoo. Previously, he served on the IACUC of Lehman College (2008-2014) and the National Zoo, Rock Creek Campus (2004). David's research has focused on a number of species and topics over the years in zoos and in the field. Topics of study have included dominance in animal societies, reproductive competition, maternal behavior, impacts of environmental enrichment and other husbandry practices on behavior, animal welfare, characterization of animal personality and personality measurement methods, affective impact of zoo exhibits on visitors, and studies of animal care staff attitudes about population management practices.
Rodney A. White
Rodney A. White M.D., is Director, Vascular Surgery Services at Long Beach MemorialCare Heart & Vascular Institute, Long Beach, California and prior Chief of Vascular Surgery at Harbor-UCLA Medical Center, Torrance, California. His academic appointment is Emeritus Professor of Surgery, UCLA School of Medicine. He is certified by the American Board of Surgery with Special Qualifications In General Vascular Surgery and by the American Board of Laser Surgery. He also has a permit as a Fluoroscopy Supervisor and Operator from the State of California, and is a Registered Vascular Technologist (RVT) certified by the American Registry of Diagnostic Medical Sonographers (ARDMS). Dr. White’s research interests include the development and evaluation of artificial implant materials, and laboratory and clinical investigation of fundamental problems and new procedures in vascular surgery. He is co-inventor of a process for fabricating microporous biomaterials including an artificial bone substitute that was recently awarded the First Annual US Congressional Golden Goose Award for federally funded research that has led to significant patient care and economic benefit. Current research programs involve the development and evaluation of endovascular surgical devices including atherectomy devices, stents, abdominal and thoracic endoluminal prostheses, and angioscopy and intraluminal ultrasound imaging technologies. Dr. White is the recipient of research grants from the National Institutes of Health, the American Heart Association and numerous national clinical studies. Dr. White is the author of more than 300 papers and 200 book chapters, and is co-author or editor of twelve books addressing a broad spectrum of topics in vascular and endovascular surgery. He is Co-Editor of the Journal of Endovascular Therapy (JEVT). He is a member of several industrial and governmental panels evaluating new medical technologies. He is past Vice-Chairman of the Board of Directors of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Dr. White is an active member of 15 regional, national and international societies and is past-President of the International Society for Endovascular Specialists, and past Secretary of the Society for Vascular Surgery.